Magenta Therapeutics Inc traded at $1.31 this Friday July 1st, increasing $0.11 or 9.17 percent since the previous trading session. Looking back, over the last four weeks, Magenta Therapeutics Inc gained 11.97 percent. Over the last 12 months, its price fell by 86.74 percent. Looking ahead, we forecast Magenta Therapeutics Inc to be priced at 1.27 by the end of this quarter and at 1.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.31
Daily Change
9.17%
Yearly
-86.74%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Magenta Therapeutics Inc 1.31 0.11 9.17% -86.74%


Magenta Therapeutics Inc
Magenta Therapeutics, Inc is a clinical-stage biotechnology company. The Company is developing medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. The Company is developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies and genetic diseases. The Company is also developing a portfolio of biologics, including antibody drug conjugates, small molecules and a cell therapy. The Company’s products include MGTA-145, CD45-ADC, MGTA-456 and MGTA-117.